KNSA

Kiniksa Pharmaceuticals Ltd.

Price

$80.80

return (12m)

143.74%

p/e

73.86

p/bv

9.11

DIVIDEND YIELD

0.00%

KNSA price

Kiniksa Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KNSA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

27.64%

3 months

50.61%

1 year

143.74%

2 years

203.42%

5 years

562.30%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals KNSA

Valuation

P/E

73.86

Sector -4.38

Industry -4.38

P/BV

9.11

Sector 2.02

Industry 2.02

P/Revenue (PSR)

7.08

Sector -4.40

Industry -4.40

EV/EBITDA

196.26

Sector -263.09

Industry -263.09

EV/EBIT

199.73

Sector -702.90

Industry -702.90

P/EBITDA

58.36

Sector -4.39

Industry -4.39

P/EBIT

59.42

Sector -4.73

Industry -4.73

P/Total Assets

6.65

Sector 1.49

Industry 1.49

P/Net Current Assets

13.96

Sector -11.70

Industry -11.70

P/Working Capital

11.98

Sector -3.19

Industry -3.19

EPS

1.03

Sector -2.14

Industry -2.14

BVPS

8.39

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

54.50%

Sector 36.74%

Industry 36.74%

EBITDA Margin

11.36%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

11.16%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

11.92%

Sector -38.22%

Industry -38.22%

Net Profit Margins

9.59%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.27

Sector 0.03

Industry 0.03

Profitability

ROE

12.33%

Sector -65.14%

Industry -65.14%

ROA

9.00%

Sector -65.53%

Industry -65.53%

ROIC

32.83%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.90

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-19.01

Sector -6.07

Industry -6.07

Net Debt / EBIT

-19.34

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.80

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.73

Sector 0.41

Industry 0.41

Liabilities/Assets

0.27

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

85.24%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Kiniksa Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$80.80

Fair Value

$13.94

Upside Return potential.

-82.74%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals KNSA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KNSA Kiniksa Pharmaceuticals Ltd.	$80.80	139.62%	0.00%	73.86	9.11	12.33%	9.59%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KNSA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd.

Average Investor10 user rating

4.0 (5 people)

United States

11 years

Founded: 2015

2018

Time since IPO - 8 years

168

Employees

Kiniksa Pharmaceuticals Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $5.96 billion, with shareholders equity totaling $654.15 million.

The company employs approximately 168 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Kiniksa Pharmaceuticals Ltd. reported $840.85 million in revenue, generating net income of $80.65 million.

Key financial metrics include a P/E ratio of 73.86, a price-to-book (P/B) ratio of 9.11, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KNSA.

Market cap

$5.96 billion

Net worth

$654.15 million

$654,150,000.00

Assets

$896.11 million

$896,110,000.00

Total Shares Outstanding

78.00 million

78,000,000

Average Daily Trading Volume

$803.17 Thousand

$803,165.74

Sector

Health Care

Industry

Biotechnology

KNSA

KNSA revenue and profits

Financial Results KNSA

DRAG THE FRAME TO SEE MORE DATA

KNSA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Kiniksa Pharmaceuticals (KNSA) today?

A cotação de Kiniksa Pharmaceuticals (KNSA) hoje está em US$ 80.80, com uma variação de 143.74% em relação ao último ano. A cotação de Kiniksa Pharmaceuticals (KNSA) iniciou o ano negociando na casa dos US$ 41.25 e hoje está em US$ 80.80. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Kiniksa Pharmaceuticals (KNSA) e dados de ações do Ibovespa e mercados internacionais.

Quando Kiniksa Pharmaceuticals (KNSA) paga dividendos?

Kiniksa Pharmaceuticals (KNSA) não distribuiu dividendos no último ano.

Is Kiniksa Pharmaceuticals (KNSA) a good investment?

Atualmente, Kiniksa Pharmaceuticals (KNSA) está cotada a US$ 80.80, com um P/L de 73.86, representando um desvio de 3,738% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 143.74 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 143.74%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Kiniksa Pharmaceuticals (KNSA) stock?

Investir em ações de Kiniksa Pharmaceuticals (KNSA) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Kiniksa Pharmaceuticals (KNSA) yield today?

A rentabilidade de Kiniksa Pharmaceuticals (KNSA) foi de 27.64% no último mês, 143.74% no último ano e 562.30% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Kiniksa Pharmaceuticals (KNSA) hoje, o investimento total seria de US$ 8,080.00, com base na cotação atual de US$ 80.80.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 19,694.19
Em 5 anos: US$ 53,513.84
Em 10 anos: US$ 8,080.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KNSA

Kiniksa Pharmaceuticals Ltd.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KNSA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING KNSA WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd.

United States

11 years

2018

168

PROFIT X PRICE KNSA

Financial Results KNSA

KNSA cash flow

Asset, Revenue and Profit Growth - KNSA

KNSA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions